238 related articles for article (PubMed ID: 25277794)
1. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.
Wassenaar CA; Conti DV; Das S; Chen P; Cook EH; Ratain MJ; Benowitz NL; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):94-104. PubMed ID: 25277794
[TBL] [Abstract][Full Text] [Related]
2. Influence of UGT2B10 Genotype on Urinary Excretion of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol- N-glucuronide by African American Smokers.
Murphy SE; von Weymarn LB; Parenteau M; Stepanov I; Tiirikainen M; LeMarchand L; Park SL
Chem Res Toxicol; 2018 Mar; 31(3):168-175. PubMed ID: 29460622
[TBL] [Abstract][Full Text] [Related]
3. Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.
Berg JZ; Mason J; Boettcher AJ; Hatsukami DK; Murphy SE
J Pharmacol Exp Ther; 2010 Jan; 332(1):202-9. PubMed ID: 19786624
[TBL] [Abstract][Full Text] [Related]
4. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
PLoS One; 2013; 8(8):e70938. PubMed ID: 23936477
[TBL] [Abstract][Full Text] [Related]
5. Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.
Taghavi T; St Helen G; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2017 Apr; 27(4):143-154. PubMed ID: 28178031
[TBL] [Abstract][Full Text] [Related]
6. Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.
Murphy SE; Sipe CJ; Choi K; Raddatz LM; Koopmeiners JS; Donny EC; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1093-1099. PubMed ID: 28264876
[No Abstract] [Full Text] [Related]
7. The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.
Bloom AJ; von Weymarn LB; Martinez M; Bierut LJ; Goate A; Murphy SE
Pharmacogenet Genomics; 2013 Dec; 23(12):706-16. PubMed ID: 24192532
[TBL] [Abstract][Full Text] [Related]
8. Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.
Chen G; Giambrone NE; Lazarus P
Pharmacogenet Genomics; 2012 Mar; 22(3):183-90. PubMed ID: 22228205
[TBL] [Abstract][Full Text] [Related]
9. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.
Chen G; Giambrone NE; Dluzen DF; Muscat JE; Berg A; Gallagher CJ; Lazarus P
Cancer Res; 2010 Oct; 70(19):7543-52. PubMed ID: 20876810
[TBL] [Abstract][Full Text] [Related]
10.
Sipe CJ; Koopmeiners JS; Donny EC; Hatsukami DK; Murphy SE
Cancer Epidemiol Biomarkers Prev; 2020 Aug; 29(8):1673-1678. PubMed ID: 32532831
[TBL] [Abstract][Full Text] [Related]
11. Glucuronidation of tobacco-specific nitrosamines by UGT2B10.
Chen G; Dellinger RW; Sun D; Spratt TE; Lazarus P
Drug Metab Dispos; 2008 May; 36(5):824-30. PubMed ID: 18238858
[TBL] [Abstract][Full Text] [Related]
12. Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers.
Chen G; Luo S; Kozlovich S; Lazarus P
Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1175-1184. PubMed ID: 27197298
[TBL] [Abstract][Full Text] [Related]
13. The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations.
Patel YM; Stram DO; Wilkens LR; Park SS; Henderson BE; Le Marchand L; Haiman CA; Murphy SE
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):119-27. PubMed ID: 25293881
[TBL] [Abstract][Full Text] [Related]
14. UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.
Berg JZ; von Weymarn LB; Thompson EA; Wickham KM; Weisensel NA; Hatsukami DK; Murphy SE
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1423-31. PubMed ID: 20501767
[TBL] [Abstract][Full Text] [Related]
15. Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups.
Murphy SE; Park SS; Thompson EF; Wilkens LR; Patel Y; Stram DO; Le Marchand L
Carcinogenesis; 2014 Nov; 35(11):2526-33. PubMed ID: 25233931
[TBL] [Abstract][Full Text] [Related]
16. Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines.
Chen G; Dellinger RW; Gallagher CJ; Sun D; Lazarus P
Pharmacogenet Genomics; 2008 Mar; 18(3):181-91. PubMed ID: 18300939
[TBL] [Abstract][Full Text] [Related]
17. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.
Chen G; Blevins-Primeau AS; Dellinger RW; Muscat JE; Lazarus P
Cancer Res; 2007 Oct; 67(19):9024-9. PubMed ID: 17909004
[TBL] [Abstract][Full Text] [Related]
18. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes.
Wiener D; Fang JL; Dossett N; Lazarus P
Cancer Res; 2004 Feb; 64(3):1190-6. PubMed ID: 14871856
[TBL] [Abstract][Full Text] [Related]
19. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes.
Lazarus P; Zheng Y; Runkle EA; Muscat JE; Wiener D
Pharmacogenet Genomics; 2005 Nov; 15(11):769-78. PubMed ID: 16220109
[TBL] [Abstract][Full Text] [Related]
20. Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance.
Liakoni E; Tyndale RF; Jacob P; Dempsey DA; Addo N; Benowitz NL
Pharmacogenet Genomics; 2021 Jul; 31(5):97-107. PubMed ID: 33675323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
